Whole-genome sequencing of 101 Polish top-elite male athletes (53 speed, 48 endurance; age 23.5 Β± 5.9 y) identified the putatively pathogenic FANCI nonsense variant rs121918164 (c.3853C>T, p.Arg1285*) in three unrelated carriers (two speed, one endurance), while TaqMan screening found zero carriers among 890 national-elite athletes, 1,009 sedentary controls, and 1,222 Polish reference genomes . Kinship analysis (max pairwise kinship 0.0026) rules out recent shared ancestry .
The unadjusted Fisher's exact p vs gnomAD non-Finnish Europeans is 1.57Γ10β»β·, but the authors' own conservative Bonferroni correction over 443,769 high-confidence loss-of-function variants yields p = 0.069 β not genome-wide significant. The authors transparently flag this and state they "cannot completely exclude the possibility that the variant was identified by chance" . This honesty is commendable but leaves the central claim exploratory at best β the finding sits exactly at the boundary where winner's-curse and post-hoc narrative (HARKing risk) are most plausible.
FANCI is the Fanconi anemia complementation group I gene, essential for interstrand crosslink repair via FANCD2 monoubiquitination . A heterozygous stop-gain at Arg1285 could plausibly cause haploinsufficiency with altered DNA-damage responses β yet no carrier physiological, medical, or performance data were available, and the mechanism connecting partial FANCI loss to elite speed/endurance performance is entirely speculative. Notably, FANCI dysregulation is documented in cancer contexts (RAS signaling restraint via lnc-FANCI-2 ; FANCI upregulation promotes ESCC progression ), but none of this directly supports an athletic-benefit mechanism.
Bottom line: A genuinely interesting, well-verified rare-variant observation that falls short of statistical significance after multiple-testing correction, lacks any mechanistic or physiological data, and rests on three carriers. Treat as hypothesis-generating, not evidence of a "beneficial pathogenic variant."
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.